59
Participants
Start Date
October 8, 2020
Primary Completion Date
March 30, 2021
Study Completion Date
April 30, 2021
Placebo
Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
fostamatinib
The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
National Institutes of Health Clinical Center, Bethesda
INOVA Health Systems, Falls Church
National Heart, Lung, and Blood Institute (NHLBI)
NIH